ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "neuropsychiatric disorders"

  • Abstract Number: 2058 • ACR Convergence 2022

    Evidence on the Construct Validity of the Perceived Deficits Questionnaire Among Adult Patients with Systemic Lupus Erythematosus

    Stefan Perera1, Jiandong Su2, Kathleen Bingham3, Mahta Kakvan1, Maria Carmela Tartaglia4, Leslet Ruttan5, Joan Wither1, May Choi6, Simone Appenzeller7, Dorcas Beaton8, Dennisse Bonilla2, Patricia Katz9, Robin Green5, Michelle Barraclough10 and Zahi Touma2, 1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, 2Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 3Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, 4University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, 5University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, 6Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, 7Unicamp, Campinas, São Paulo, Brazil, 8Institute for Work & Health, Toronto, ON, Canada, 9UCSF, San Rafael, CA, 10Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada

    Background/Purpose: Cognitive impairment (CI) is prevalent in SLE and negatively impacts social and occupational engagement. There is a need for a patient-reported outcome measure (PROM)…
  • Abstract Number: 2223 • ACR Convergence 2022

    Transcriptome Profiling and Autoimmunity-related Serological Markers Identify Tumour Protein P53 and Complement C3a Receptor 1 as Drug Targets in Neuropsychiatric Systemic Lupus Erythematosus

    Julius Lindblom1, Daniel Toro-Domínguez2, Elena Carnero-Montoro2, Maria Orietta Borghi3, Jessica Castillo4, Ellen Iacobaeus1, Yvonne Enman5, Chandra Mohan4, Marta Alarcon-Riquelme2, Guillermo Barturen2 and Ioannis Parodis1, 1Karolinska Institutet, Stockholm, Sweden, 2Center for Genomics and Oncological Research (GENYO), Granada, Spain, 3Università degli Studi di Milano and Istituto Auxologico Italiano, Milano, Italy, 4University of Houston, Houston, TX, 5Karolinska Institutet, Sundbyberg, Sweden

    Background/Purpose: Involvement of the nervous system is a common but poorly understood manifestation of SLE, termed NPSLE. Although studies have reported varying prevalence estimates (Unterman…
  • Abstract Number: 2265 • ACR Convergence 2022

    Autoimmune RNA Dysregulation and Seizures: Therapeutic Prospects in Neuropsychiatric Systemic Lupus Erythematosus

    Henri Tiedge1, ILHAM MUSLIMOV2, Valerio Berardi2, Stacy Stephenson3, Ellen M. Ginzler4, Anca Askanase5 and John Hanly6, 1SUNY, Downstate Medical Center, Brooklyn, NY, 2SUNY Downstate Medical Center, Brooklyn, NY, 3SUNY Downstate Medical Center, dep. of Comparative Medicine, Brooklyn, NY, 4SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, 5Columbia University Medical Center, New York, NY, 6Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada

    Background/Purpose: Neuropsychiatric (NP) involvement is common in systemic lupus erythematosus (SLE). Manifestations often include seizures and cognitive impairment but underlying etiology remains poorly understood. Brain…
  • Abstract Number: 0321 • ACR Convergence 2022

    M-Phase Phosphoprotein 1 (MPP-1) Autoantibodies as a Potential Biomarker for Cranial Neuropathies in an International SLE Inception Cohort

    Eugene Krustev1, John Hanly2, Ricky Chin3, Katherine Buhler1, Francesca S Cardwell4, Murray Urowitz5, Caroline Gordon6, Sang-Cheol Bae7, Juanita Romero-Diaz8, Jorge Sanchez-Guerrero9, Sasha Bernatsky10, Daniel Wallace11, David Isenberg12, Anisur Rahman13, Joan Merrill14, Paul R Fortin15, Dafna Gladman16, Ian N. Bruce17, Michelle Petri18, Ellen M. Ginzler19, Mary Anne Dooley20, Rosalind Ramsey-Goldman21, Susan Manzi22, Andreas Jönsen23, Graciela Alarcón24, Ronald van Vollenhoven25, Cynthia Aranow26, Meggan Mackay26, Guillermo Ruiz-Irastorza27, S. Sam Lim28, Murat İnanç29, Kenneth Kalunian30, Soren Jacobsen31, Christine Peschken32, Diane Kamen33, Anca Askanase34, Jill Buyon35, Marvin Fritzler1, Ann E Clarke36 and May Choi37, 1University of Calgary, Calgary, AB, Canada, 2Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, 3University of Calgary, Ottawa, ON, Canada, 4University of Waterloo, Department of Geography & Environmental Management, Burlington, ON, Canada, 5University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, 6Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 7Hanyang University Medical Center, Seoul, Republic of Korea, 8Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, 9Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, 10Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 11Cedars-Sinai Medical Center, Los Angeles, CA, 12University College London, London, United Kingdom, 13Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 14Oklahoma Medical Research Foundation, Oklahoma City, OK, 15Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, 16Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 17Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, 18Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 19SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, 20Raleigh Neurology Associates, Chapel Hill, NC, 21Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, 22Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, 23Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, 24The University of Alabama at Birmingham, Oakland, 25Amsterdam University Medical Centers, Amsterdam, Netherlands, 26Feinstein Institutes for Medical Research, Manhasset, NY, 27Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Spain, 28Emory University, Atlanta, GA, 29Istanbul University Faculty of Medicine, Istanbul, Turkey, 30University of California San Diego, La Jolla, CA, 31Rigshospitalet, Copenhagen, Denmark, 32University of Manitoba, Winnipeg, MB, Canada, 33Medical University of South Carolina, Charleston, SC, 34Columbia University Medical Center, New York, NY, 35NYU Grossman School of Medicine, New York, NY, 36University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, 37Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada

    Background/Purpose: We previously reported in a single centre prevalent SLE cohort that antibodies against the cytokinesis-associated protein M-Phase Phosphoprotein 1 (anti-MPP-1) were associated with SLE-related…
  • Abstract Number: 0332 • ACR Convergence 2022

    Soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in Cerebrospinal Fluid Relating to Development of Diffuse Psychiatric/Neuropsychological Syndromes in Patients with Systemic Lupus Erythematosus (diffuse NPSLE)

    Yoshiyuki Arinuma1, Yasuhiro Hasegawa2, Yu Matsueda2, Kenji Oku3 and Kunihiro Yamaoka4, 1Kitasato University, Kanagawa, Japan, 2Kitasato University School of Medicine, Sagamihara, Japan, 3Kitasato University, Chigasaki, Japan, 4Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan

    Background/Purpose: Microglial activation is critical for behavioral abnormalities in a mouse model of diffuse NPSLE following anti-glutamate receptor subunit GluN2 antibody (anti-GluN2) exposure to neurons.…
  • Abstract Number: 0659 • ACR Convergence 2022

    Comprehensive Proteomic Screen of Murine Lupus Serum and Cerebrospinal Fluid Uncovers Diagnostic and Therapeutic Targets

    Joshua Reynolds1, Chandra Mohan2, Yaxi Li2 and Chaim Putterman1, 1Albert Einstein College of Medicine, Bronx, NY, 2University of Houston, Houston, TX

    Background/Purpose: Up to 50% of SLE patients experience neuropsychiatric involvement (neuropsychiatric lupus, or NPLSE) through an unknown mechanism. Diagnosis currently relies on clinical criteria and…
  • Abstract Number: 0968 • ACR Convergence 2022

    Neuropsychological Outcome of Children Born to Women with Systemic Sclerosis: Assessment Through a Self-administered Multidisciplinary Questionnaire in a Monocentric Cohort

    Eleonora Pedretti1, Laura Andreoli1, Liala Moschetti1, Cecilia Nalli1, Anna Molinaro2, Jessica Galli2, Elisa Fazzi2, Franco Franceschini1, Angela Tincani3, Paolo Airò4 and Maria Grazia Lazzaroni1, 1Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, 2Unit of Child and Adolescent Neuropsychiatry, ASST Spedali Civili and University of Brescia, Brescia, Italy, 3Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Gussago, Italy, 4Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy

    Background/Purpose: In the last years, the rate of successful pregnancies has significantly increased in Systemic Sclerosis (SSc)1 women. However, the long-term outcome of their children…
  • Abstract Number: 0345 • ACR Convergence 2021

    Anti-MPP-1 Autoantibodies in Systemic Lupus Erythematosus: A Potential Biomarker for Neuropsychiatric Manifestations

    Eugene Krustev1, Katherine Buhler1, Francesca Cardwell2, Marvin Fritzler1, Ann Clarke1 and May Choi3, 1University of Calgary, Calgary, AB, Canada, 2University of Waterloo, Burlington, ON, Canada, 3Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada

    Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) can involve the central (CNS) and peripheral nervous system (PNS). Several autoantibodies have been associated with CNS NPSLE including…
  • Abstract Number: 0473 • ACR Convergence 2021

    Disease-Associated Microglia Are Implicated in Neuropsychiatric Manifestations of Systemic Lupus Erythematosus

    Hadijat Makinde1, Shang-Yang Chen1, Elise Mike2, Chaim Putterman2, Deborah Winter3 and Carla Cuda1, 1Northwestern University, Chicago, IL, 2Albert Einstein College of Medicine, Bronx, NY, 3Northwestern University Division of Rheumatology, Chicago, IL

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune syndrome affecting multiple organs, including the brain. Though 50% of patients may experience neuropsychiatric symptoms (NPSLE),…
  • Abstract Number: 0536 • ACR Convergence 2021

    The EIF4 Translational Inhibitor Pateamine a Improves Immunological and Neurological Functions in BXSB.yaa Lupus Mice

    Gonzalo Gómez-Hernández1, Nieves Varela1, Harini Bagavant2, Guillermo Barturen1, Marta E. Alarcon-Riquelme1 and Maria Morell1, 1GENYO.Center for Genomics and Oncological Research, Granada, Spain, 2Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by loss of tolerance and activation of the immune response. Clinical manifestations are heterogeneous and…
  • Abstract Number: 0540 • ACR Convergence 2021

    Behavioral Deficits May Precede Influx of Brain-Infiltrating Macrophages in Neuropsychiatric Symptoms of Systemic Lupus Erythematosus

    Hadijat Makinde, Miranda Gurra, Yidan Wang, Sara Radecki and Carla Cuda, Northwestern University, Chicago, IL

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects many end organs including the brain. Despite a prevalence of over 50% in…
  • Abstract Number: 0881 • ACR Convergence 2021

    Economic Evaluation of Neuropsychiatric (NP) Lupus in an International Inception Cohort Using a Multistate Model Approach

    Ann Clarke1, John Hanly2, Yvan St.Pierre3, Caroline Gordon4, Sang-Cheol Bae5, Juanita Romero-Diaz6, Jorge Sanchez-Guerrero7, Sasha Bernatsky8, Daniel Wallace9, David Isenberg10, Anisur Rahman11, Joan Merrill12, Paul R Fortin13, Dafna Gladman14, Murray Urowitz15, Ian N. Bruce16, Michelle Petri17, Ellen Ginzler18, Mary Anne Dooley19, Rosalind Ramsey-Goldman20, Susan Manzi21, Andreas Jnsen22, Graciela Alarcn23, Ronald van Vollenhoven24, Cynthia Aranow25, Meggan Mackay25, Guillermo Ruiz-Irastorza26, S Sam Lim27, Murat Inanc28, Kenneth Kalunian29, Soren Jacobsen30, Christine Peschken31, Diane Kamen32, Anca Askanase33 and Vernon Farewell34, 1University of Calgary, Calgary, AB, Canada, 2Dalhousie University, Halifax, NS, Canada, 3Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 4Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 5Hanyang University Medical Center, Seoul, Republic of Korea, 6Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, 7Instituto Nacional de Ciencias Médicas y Nutrición, Inmunología y Reumatología, Mexico City, Mexico, 8McGill University, Montréal, QC, Canada, 9Cedars-Sinai, Los Angeles, CA, 10Centre for Rheumatology, University College London, London, United Kingdom, 11University College London, London, United Kingdom, 12Oklahoma Medical Research Foundation, Oklahoma City, OK, 13CHU de Quebec - Universite Laval, Québec City, QC, Canada, 14Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 15Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, 16University of Manchester, Manchester, United Kingdom, 17Johns Hopkins University School of Medicine, Baltimore, MD, 18SUNY Downstate Health Sciences University, Brooklyn, NY, 19Raleigh Neurology Associates, Chapel Hill, NC, 20Northwestern University, Chicago, IL, 21Allegheny Health Network, Wexford, PA, 22Lund University, Lund, Sweden, 23University of Alabama at Birmingham, Birmingham, AL, 24Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, 25Feinstein Institutes for Medical Research, Manhasset, NY, 26Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, 27Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, 28Istanbul University Faculty of Medicine, Istanbul, Turkey, 29UC San Diego, La Jolla, CA, 30Rigshospitalet, Copenhagen, Denmark, 31University of Manitoba, Winnipeg, MB, Canada, 32Medical University of South Carolina, Charleston, SC, 33Columbia University Medical Center, New York, NY, 34University of Cambridge, Cambridge, United Kingdom

    Background/Purpose: Little is known about the economic burden of NP lupus. We estimated annual and cumulative direct and indirect costs (DC, IC) associated with NP…
  • Abstract Number: 1481 • ACR Convergence 2021

    Malondialdehyde-acetaldehyde Antibodies Occur in Systemic Lupus Erythematosus and Associate Specifically with Neuropsychiatric Involvement

    Rory Monahan, Michelle van Beukel, Nicole Borggreven, Margreet Kloppenburg, Tom WJ Huizinga, Gerda Steup-Beekman and Leendert Trouw, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogenous autoimmune disease characterized by a global loss of self-tolerance. Although autoantibodies are an important hallmark of SLE,…
  • Abstract Number: 0835 • ACR Convergence 2020

    Pathogenic Effect of Chronic Stress-induced interleukin-12/23p40 on Neuropsychiatric System in Lupus-prone Mouse

    Nobuya Abe1, Kenji Oku1, Yuichiro Fujieda1, Nobuhiko Takahashi2, Kohei Karino1, Michihito Kono1, Masaru Kato1, Yuki Tanaka3, Rie Hasebe4, Olga Amengual1, Miwako Yamasaki5, Masahiko Watanabe5, Masaaki Murakami3 and Tatsuya Atsumi6, 1Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, 2Division of Molecular Psychoimmunology, Institute for Genetic Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 3Division of Molecular Psychoimmunology, Institute for Genetic Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, 4Biomedical Animal Research Laboratory, Institute for Genetic Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, 5Department of Anatomy, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, 6Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan

    Background/Purpose:Neuropsychiatric system is one of the major organs affected in systemic lupus erythematosus (SLE). However, the pathogenesis of neuropsychiatric SLE (NPSLE) has not been fully…
  • Abstract Number: 0854 • ACR Convergence 2020

    Mortality and Adverse Events of Special Interest in Adult Patients with Systemic Lupus Erythematosus Receiving Intravenous Belimumab: A Post Hoc Descriptive Summary of Serious Psychiatric Events

    Saira Sheikh1, Ricardo Acayaba de Toledo2, Laura Geraldino-Pardilla3, Julia Harris4, Regina Kurrasch5, Andrew Liu4, Kathleen Maksimowicz-McKinnon6, Holly Quasny7, David Roth5, Lilian Soto8 and Rajesh Punwaney5, 1University of North Carolina Thurston Arthritis Research Center, Chapel Hill, 2Faculdade de Medicina de São José do Rio Preto, São Paulo, Brazil, 3Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, 4GlaxoSmithKline, Uxbridge, United Kingdom, 5GlaxoSmithKline, Collegeville, 6Henry Ford Hospital, Detroit, 7GlaxoSmithKline, Research Triangle Park, 8Facultad de Medicina, Clinical Hospital of Universidad de Chile, Santiago, Chile

    Background/Purpose: Intravenous (IV) belimumab (BEL) is approved in patients ≥5 years of age with active systemic lupus erythematosus (SLE). Results of the BASE study (the…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology